To characterize the impact of exogenous TPO on HSC-derived iKMT2A-MLLT3-driven AML, we compared the gene expression signatures from emerging leukemic cells (“bulk”) (Supplementary Fig. 4A). The gene discussed is TPO; the disease is acute myeloid leukemia.